key: cord-0298683-kvzxuvq9
authors: Mills, M.; Hajian, P.; Bakhash, S. M.; Xie, H.; Mantzke, D.; Zhu, H.; Huang, M.; Pepper, G.; Jerome, K.; Roychoudhury, P.; Greninger, A.
title: Rapid and Accurate Identification of SARS-CoV-2 Omicron Variants Using Droplet Digital PCR (RT-ddPCR)
date: 2022-01-12
journal: nan
DOI: 10.1101/2022.01.11.22268981
sha: a2d8d18e7ffad0c688a445538a3460d172d0c00e
doc_id: 298683
cord_uid: kvzxuvq9

Background Mutations in the receptor binding domain of the SARS-CoV-2 Spike protein are associated with increased transmission or substantial reductions in vaccine efficacy, including in the recently described Omicron variant. The changing frequencies of these mutations combined with their differing susceptibility to available therapies have posed significant problems for clinicians and public health professionals. Objective To develop an assay capable of rapidly and accurately identifying variants including Omicron in clinical specimens to enable case tracking and/or selection of appropriate clinical treatment. Study Design Using three duplex RT-ddPCR reactions targeting four amino acids, we tested 419 positive clinical specimens from February to December 2021 during a period of rapidly shifting variant prevalences and compared genotyping results to genome sequences for each sample, determining the sensitivity and specificity of the assay for each variant. Results Mutation determinations for 99.7% of detected samples agree with NGS data for those samples, and are accurate despite wide variation in RNA concentration and potential confounding factors like transport medium, presence of additional respiratory viruses, and additional mutations in primer and probe sequences. The assay accurately identified the first 15 Omicron variants in our laboratory including the first Omicron in Washington State and discriminated against S-gene dropout Delta specimen. Conclusion We describe an accurate, precise, and specific RT-ddPCR assay for variant detection that remains robust despite being designed prior the emergence of Delta and Omicron variants. The assay can quickly identify mutations in current and past SARS-CoV-2 variants, and can be adapted to future mutations.

1 3 2 chloro-7'-phenyl-1,4-dichloro-6-carboxy-fluoroscein. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 12, 2022. ; https://doi.org/10.1101/2022.01.11.22268981 doi: medRxiv preprint 1 4 0 selected to represent the amino acids at the four RBD sites present at the time (Table 3) .

One high-concentration clinical specimen from each lineage was identified in the UWVL 1 4 2 SARS-CoV-2 repository based on NGS results, and diluted in PBS into high-1 4 3 concentration (~5000 copies/µl) mutation controls. 

Amino Acid Target  Lineage  417  452  484  501  D614G K were screened by TaqPath assay as previously described.

[36] Sixteen of these were 1 5 2 identified as S-gene dropouts and were tested in the RT-ddPCR assay.

This study was approved under a waiver of consent by the University of . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 12, 2022. ; https://doi.org/10.1101/2022.01.11.22268981 doi: medRxiv preprint 1 6 0 TaqMan probe detection: when a probe is bound to the template, amplification separates 1 6 1 the dye on the 5' end of the probe from the quencher on the 3' end of the probe, causing a 1 6 2 release of fluorescent dye. However, when the probe binds poorly to the template because 1 6 3 of differences in probe and template sequence, the dye is cleaved less frequently and less 1 6 4 fluorescence is released inside that droplet. At the end of the PCR reaction, the 1 6 5 fluorescence within each droplet is measured. The amplitude (brightness) of fluorescence 1 6 6 within each droplet indicates how well the probe bound to the template and therefore can 1 6 7 be used to determine the mutation state of that template.

Using four high-concentration specimens with each allele (Supplement 2), we To confirm that extra copies of template do not increase fluorescence amplitude 1 7 5

within a droplet, we tested the four high-concentration specimens along with serial 10-1 7 6 fold dilutions of each, and compared amplitudes (Fig. 2, Supplement 2) . RT-ddPCR 1 7 7 assays contain 10k+ droplets each, so template concentration ranged from 1 to >50 copies 1 7 8 per droplet. Increased concentration did in some cases change amplitude (e.g., 417N and 1 7 9 452R), but these are still readily distinguishable from high-and low-concentration CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 12, 2022. ; https://doi.org/10.1101/2022.01.11.22268981 doi: medRxiv preprint 1 8 3 dilutions of one specimen per mutation, with four replicates per concentration (Table 4) .

Each dilution was also measured in RT-PCR with E gene primers and probe[43] in 1 8 5 duplicate. Higher template concentrations were necessary to obtain at least 3 positive 1 8 6 droplets for mismatch alleles (i.e., 417K and 484Q), but for the targets definitively . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 12, 2022. did not affect the accuracy of mutation determination for spiked-in controls (Table 6 ). were tested both alone and with spiked-in RNA from each allele in all assay reactions.

Allele determinations were made based on droplet amplitudes. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 12, 2022. ; https://doi.org/10.1101/2022.01.11.22268981 doi: medRxiv preprint Between November 29 and December 8, 2021, we tested 2657 SARS-CoV-2 2 4 4 positive clinical specimens by TaqPath assay, with 16 clear SGTF results. These 16 2 4 5 specimens were tested by the RT-ddPCR assay along with five non-SGTF specimens 2 4 6 ( Fig. 4) . All non-SGTF specimens were clearly Delta. The first SGTF was identified as is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 12, 2022. ; https://doi.org/10.1101/2022.01.11.22268981 doi: medRxiv preprint 9 9

Hematology Am Soc Hematol Educ Program (2021 

Passive immune therapies: another tool against COVID-19